ORMP Overview

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Wall Street analysts forecast ORMP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORMP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Oramed Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

Oramed Pharmaceuticals Inc. EPS for the last quarter amounts to 1.13 USD, decreased -335.42

Oramed Pharmaceuticals Inc (ORMP) has 13 emplpoyees as of March 14 2026.

Today ORMP has the market capitalization of 136.52M USD.